These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18253122)

  • 1. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
    Mellemkjaer L; Dahl C; Olsen JH; Bertelsen L; Guldberg P; Christensen J; Børresen-Dale AL; Stovall M; Langholz B; Bernstein L; Lynch CF; Malone KE; Haile RW; Andersson M; Thomas DC; Concannon P; Capanu M; Boice JD; ; Bernstein JL
    Br J Cancer; 2008 Feb; 98(4):728-33. PubMed ID: 18253122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
    Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
    Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
    Reiner AS; Sisti J; John EM; Lynch CF; Brooks JD; Mellemkjær L; Boice JD; Knight JA; Concannon P; Capanu M; Tischkowitz M; Robson M; Liang X; Woods M; Conti DV; Duggan D; Shore R; Stram DO; Thomas DC; Malone KE; Bernstein L; ; Bernstein JL
    J Clin Oncol; 2018 May; 36(15):1513-1520. PubMed ID: 29620998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
    de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
    J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
    de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.
    Bernstein JL; Teraoka SN; John EM; Andrulis IL; Knight JA; Lapinski R; Olson ER; Wolitzer AL; Seminara D; Whittemore AS; Concannon P
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):348-52. PubMed ID: 16492927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.
    Broeks A; Braaf LM; Huseinovic A; Nooijen A; Urbanus J; Hogervorst FB; Schmidt MK; Klijn JG; Russell NS; Van Leeuwen FE; Van 't Veer LJ
    Breast Cancer Res; 2007; 9(2):R26. PubMed ID: 17428320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families.
    Abud J; Koehler-Santos P; Ashton-Prolla P; Prolla JC;
    Arq Gastroenterol; 2012 Dec; 49(4):273-8. PubMed ID: 23329222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
    Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
    Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A
    Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
    Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
    Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
    Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
    Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.
    Muranen TA; Greco D; Fagerholm R; Kilpivaara O; Kämpjärvi K; Aittomäki K; Blomqvist C; Heikkilä P; Borg A; Nevanlinna H
    Breast Cancer Res; 2011 Sep; 13(5):R90. PubMed ID: 21542898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.
    Broeks A; de Witte L; Nooijen A; Huseinovic A; Klijn JG; van Leeuwen FE; Russell NS; van't Veer LJ
    Breast Cancer Res Treat; 2004 Jan; 83(1):91-3. PubMed ID: 14997059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
    Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; Collaborators N; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; Investigators A; Investigators K; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Marchand LL; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
    Res Sq; 2023 Feb; ():. PubMed ID: 36824750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers.
    Thompson D; Seal S; Schutte M; McGuffog L; Barfoot R; Renwick A; Eeles R; Sodha N; Houlston R; Shanley S; Klijn J; Wasielewski M; Chang-Claude J; Futreal PA; Weber BL; Nathanson KL; Stratton M; Meijers-Heijboer H; Rahman N; Easton DF
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2542-5. PubMed ID: 17164383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.